A 12-Month Study To Evaluate The Safety And Tolerability Of Pregabalin As Add-On Therapy In Pediatric Subjects 1 Month To 16 Years Of Age With Partial Onset Seizures And Pediatric And Adult Subjects 5 To 65 Years Of Age With Primary Generalized Tonic-Clonic Seizures

This study is currently recruiting participants.
Verified September 2013 by Pfizer
Information provided by (Responsible Party):
ClinicalTrials.gov Identifier:
First received: October 17, 2011
Last updated: March 25, 2014
Last verified: September 2013

Study A0081106 is a 12-month open-label study to evaluate the long term safety and tolerability of pregabalin as add-on therapy in pediatric subjects 1 month to 16 years of age with partial onset seizures and pediatric and adult subjects 5 to 65 years of age with primary generalized tonic-clonic seizures. Pregabalin will be administered in equally divided daily doses for 1 year, in either capsule or liquid oral formulation.

Condition Intervention Phase
Epilepsy, Partial Seizures
Drug: Pregabalin
Phase 3

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A 12-Month Open-Label Study To Evaluate The Safety And Tolerability Of Pregabalin As Adjunctive Therapy In Children 1 Month To 16 Years Of Age With Partial Onset Seizures And Child And Adult Subjects 5 To 65 Years Of Age With Primary Generalized Tonic-Clonic Seizures

Resource links provided by NLM:

Further study details as provided by Pfizer:

Primary Outcome Measures:
  • SAE's (serious adverse event) and AE's (adverse events) [ Time Frame: continuously for up to one year ] [ Designated as safety issue: Yes ]
  • Vital signs [ Time Frame: change from baseline will be assessed at 2, 6, 9 , and 12 months ] [ Designated as safety issue: Yes ]
  • Physical exams to assess change from baseline for physical state of limbs, torso, and organs and Neurological exams to assess change from baseline for measures of peripheral and central nervous system function. [ Time Frame: change from baseline will be assessed at 6 and 12 months ] [ Designated as safety issue: Yes ]
  • Clinical laboratory data (hematology , chemistry, urinalysis [ Time Frame: change from baseline will be assessed at 6 and 12 months ] [ Designated as safety issue: Yes ]
  • Electrocardiograms [ Time Frame: change from baseline will be assessed at 12 months ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Suicidality assessments [ Time Frame: every visit for up to 1 year ] [ Designated as safety issue: Yes ]
  • Cognitive testing [ Time Frame: change from baseline will be assessed at 12 months ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 300
Study Start Date: February 2012
Estimated Study Completion Date: November 2015
Estimated Primary Completion Date: November 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Open
Pregabalin open label flexible dose
Drug: Pregabalin
Pregabalin administered twice daily in equally divided doses as either capsule or liquid oral formulations. Children less than 17 years of age will receive from 2.5 mg/kg/day to 10.0 mg/kg/day (maximum 600 mg/day. Adults 17 and older will receive from 150 mg/day to 600 mg/day.
Other Name: Lyrica


Ages Eligible for Study:   1 Month to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subjects and/or parent(s)/legally acceptable representative must be considered willing and able to sign consent, and complete daily dosing and seizure diaries and complete all scheduled visits.
  • Male and female epilepsy subjects, 1 month to 65 years of age inclusive on the date of the Screening Visit.
  • Diagnosis of epilepsy with seizures classified as simple partial, complex partial, or partial becoming secondarily generalized, or primary generalized tonic-clonic seizures according to the International League Against Epilepsy (ILAE 2010) Diagnosis Criteria.
  • Partial onset seizure subjects must have had an average of at least 3 seizures per 28 day period in the 3 months prior to screening.
  • Currently receiving a stable dose of 1 to 3 antiepileptic drugs (stable within 28 days prior to screening).

Exclusion Criteria:

  • Lennox-Gastaut syndrome, Infantile Spasms, Absence seizures, BECT (Benign Epilepsy with Centrotemporal Spikes), and Dravet syndrome,
  • A current diagnosis of febrile seizures or any febrile seizure within 1 year of screening.
  • Status epilepticus within 1 year prior to visit 1.
  • Seizures related to drugs, alcohol, or acute medical illness.
  • Progressive structural CNS lesion or a progressive encephalopathy.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01463306

Contact: Pfizer CT.gov Call Center 1-800-718-1021

  Show 77 Study Locations
Sponsors and Collaborators
Study Director: Pfizer CT.gov Call Center Pfizer
  More Information

Additional Information:
No publications provided

Responsible Party: Pfizer
ClinicalTrials.gov Identifier: NCT01463306     History of Changes
Other Study ID Numbers: A0081106
Study First Received: October 17, 2011
Last Updated: March 25, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by Pfizer:
partial onset seizures
primary generalized tonic-clonic seizures
long term

Additional relevant MeSH terms:
Epilepsies, Partial
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Neurologic Manifestations
Signs and Symptoms
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Pharmacologic Actions
Central Nervous System Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on April 17, 2014